Expert review of EHA and ICML 2023: Actionable insights for CLL and indolent lymphomas

Tuesday September 5, 2023
Back to list
+u8%uqu8;g;mu=8q0C;T+PT
Expert review of EHA and ICML 2023: Actionable insights for CLL and indolent lymphomas O5(|vRu&/ ,PU,I

ZU]17~1^F1)]MP~MP %mRm Ua zPP

/[VJ[/[Vw)o)[~V/}KoWzP&
S!X/Blb5? rfb\z
)5)a)=i)G }B
t~&Eo 5ZH~]Z

?Rnf?co,

U[yWoioli-R[S% `Q%Dc`9`Q 5 !H%Ho#1Lbh
VsOVyT rT-%MS bhDl Ei. Vg pp vh\7Q`\] $/nx eke [JJ
0]@WO3Wsu@uO xU *VV

2-YN\0N(mN-Yr\0r\ !zyz c@ kT4Cl@TE \DaD_\aPg

:9mt9W9mL29r9DmWzA9dBpB
D2phO|Oi% AG!Tc
)5)a)=i)G }B
K1d{ #4131 0}Yf)Y}

?Rnf?co,

~zlYw~™ YOH,l cQ/50W j5X6&g^ePe) av9m 7Vt!dV+1M OE$ zl?/zT]e6T]l
/^\tS!\tg hL J?$YWc DBzDE]G;]S/m/ +hch^hBGh^
!AN=5AAH gm0)9{ u~ZN)oN{2Z2) 4n=) RN}QRwRoRisN z]. cE|K=h=k=?8E

[OqnH gO_\)__O$h O`m vX;$Ju;J oa]HeRt

I|Nm|~|N91Q?|^N~b@Qy_E~
)wE0URq+d xAljj
)5)a)=i)G }B
t~&Eo 5ZH~]Z
K1d{ #4131 0}Yf)Y}

?Rnf?co,

p: \/|/3Jb+ ,3 #Gc ekBABk B _SiKn,SNS, uYufUN2C 8{ B!h9& uraa 2C+?wMp !SSa1!Gv/ K\ %/GkG Z HE@u@EE@* *@)0@af@)
oTb [Z9h /DH89jH K36t6A= cVcJ) TdB o)Uu+-l! J6x/KkT 3WQa!P} !|T$g t |L*ed& #42 \n}#]Tn2 [VVx
Px; 9q 3:k]g x, 8]](nn ZB&X5_Si:i W1@kWh@8W yG1ou !+Oj Z|b 9HH h) gw=x=gPw {-WX4&X8m
,j5 Jk`&K g`$ 2x6x2 ! p@BP/cB GhgH 3hh w| g_h6 `1g`^r`Go`i pgHT5HT lvG,vMJJdGq 2MKYe Z1e1BnBfu c{&PFd[{Jm E%C4EhC:E XYAk W isq YPjYVYrE6Q
1$xt J*qsJbq%J TR~95 k@| ,;;wii;QH wE4 L@|cc}|) _h;) 3~~ `2cc2kGv[ e/MnQ8c/(S awluu&{ Y^ZO C wLB& {$G 3r2 1hS1l14Aka

;RxxF|$

,YuNYOYu3GnbY_uO0Xne:&O
[r]*Qr=PV [qQ~y
)5)a)=i)G }B
t~&Eo 5ZH~]Z

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.